Colchicine

證據等級: L5

預測適應症: 3 個

Colchicine: From Gout to Plasmodium falciparum Malaria

One-Sentence Summary

Colchicine is an ancient alkaloid derived from Colchicum autumnale, long established as the first-line treatment for acute gout and familial Mediterranean fever (FMF) through its microtubule-disrupting and anti-inflammatory properties. The TxGNN model predicts it may also be effective for Plasmodium falciparum malaria — the most lethal form of human malaria — with 0 clinical trials and 6 preclinical publications currently identified, all of which are Tier 3 in vitro mechanistic studies. Overall, evidence for this specific repurposing direction remains at the preclinical hypothesis stage (Evidence Level L4), and the current recommendation is Hold pending direct experimental validation.

Quick Overview

Item	Content
Original Indication	Gout (acute flares); Familial Mediterranean Fever — internationally approved, but not registered in Taiwan
Predicted New Indication	Plasmodium falciparum malaria
TxGNN Prediction Score	99.60%
Evidence Level	L4
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Colchicine binds with high affinity to the colchicine-binding site on α/β-tubulin heterodimers, preventing GTP-dependent polymerization and collapsing the microtubule network. In human physiology, this disrupts neutrophil chemotaxis, inhibits NLRP3/Pyrin inflammasome assembly (which depends on cytoskeletal integrity), and reduces secretion of the pro-inflammatory cytokines IL-1β and IL-18. These mechanisms underpin its established efficacy in gout and FMF.

Plasmodium falciparum maintains its own α/β-tubulin system, independent from the host cell's cytoskeleton. The parasite depends on microtubules for schizogony (nuclear division within red blood cells) and for spindle apparatus formation during gametocyte development. In principle, a compound that disrupts plasmodial microtubule assembly could arrest parasite replication. Supporting this class-level rationale, in vitro studies on structurally related tubulin-binding compounds — including Colcemid (a colchicine analogue) and tubulozole isomers — have demonstrated activity against P. falciparum, providing indirect mechanistic plausibility.

However, the central challenge is selectivity: plasmodial tubulins share high structural similarity with human tubulins, and no published data demonstrates that colchicine itself can kill P. falciparum at sub-toxic human doses. None of the 6 identified publications directly test colchicine against the parasite — they describe structurally analogous compounds or general cytoskeletal biology in the malaria context. The TxGNN prediction likely reflects microtubule-targeting class similarity within the knowledge graph, rather than direct empirical evidence for colchicine itself.

Clinical Trial Evidence

Currently no related clinical trials registered for Colchicine in Plasmodium falciparum malaria.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2655935	1989	In vitro pharmacology	Cell Biology International Reports	Nine tubulin-binding compounds tested against P. falciparum in vitro; plasmodial tubulins appear molecularly distinct from mammalian proteins; Tubulozole-T (inactive in mammals) shows antimalarial promise as indirect evidence for the drug class
2670249	1989	In vitro pharmacology	Cell Biology International Reports	Confirms tubulin-binding compounds have in vitro antimalarial activity; cytochalasin B (actin-binding) also tested, establishing that cytoskeletal disruption broadly affects parasite viability
2221861	1990	In vitro mechanistic	Antimicrobial Agents and Chemotherapy	Tubulozole isomers inhibit P. falciparum protein biosynthesis; Colcemid (a direct colchicine analogue) produces similar effects, suggesting the colchicine-binding site on plasmodial tubulin is a viable target
23505424	2013	In vitro mechanistic	PLoS ONE	Curcumin disrupts P. falciparum microtubule structure; demonstrates that diverse microtubule-targeting agents can impair parasite viability, supporting the broader mechanistic hypothesis
6362934	1984	Serological study	Clinical and Experimental Immunology	82% of acute malaria patients show IgM antibodies to cytoskeletal intermediate filaments; highlights cytoskeletal involvement in malaria immunopathology, providing biological context
7511206	1994	Molecular biology	Molecular and Cellular Biology	pfmdr1 (P-glycoprotein homologue) expression linked to chloroquine resistance; contextualizes how drug efflux mechanisms in P. falciparum may also limit microtubule-targeting agents

Taiwan Market Information

Colchicine currently has no registered authorizations in Taiwan (市場狀態：未上市). No product listings, dosage forms, or approved indications are available from the Taiwan TFDA database.

Colchicine is approved in other jurisdictions — including the United States (Colcrys®, Mitigare®) for acute gout and familial Mediterranean fever — but these approvals do not apply to the Taiwan market.

Safety Considerations

Narrow Therapeutic Index: Colchicine has no clear dose boundary distinguishing non-toxic, toxic, and lethal exposure. Unintentional poisoning is common and associated with poor clinical outcomes (PMID 20586571). This is a critical constraint when evaluating any new indication, particularly one (malaria) that may require sustained dosing at concentrations approaching the toxic threshold.

Conclusion and Next Steps

Decision: Hold

Rationale: All 6 supporting publications are Tier 3 in vitro mechanistic studies involving related compounds rather than colchicine itself; no clinical trial data exists for this indication. Colchicine's narrow therapeutic index, combined with the structural similarity between plasmodial and human tubulins, creates a fundamental selectivity barrier that current evidence does not address.

To proceed, the following is needed:

Direct in vitro testing of colchicine (not structural analogues) against P. falciparum at clinically achievable plasma concentrations
Determination of the selectivity index (IC₅₀ parasite / IC₅₀ mammalian cytotoxicity); a value >10 would be the minimum threshold for further development
Structural or biophysical studies confirming differential binding affinity to plasmodial vs. human α/β-tubulin
In vivo proof-of-concept in an animal malaria model (e.g., Plasmodium berghei murine model)
Full safety profiling and pharmacokinetic assessment at antimalarial-relevant doses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.